ĐẶC ĐIỂM BỆNH NHÂN UNG THƯ BIỂU MÔ TẾ BÀO GAN ĐIỀU TRỊ BẰNG PHÁC ĐỒ ATEZOLIZUMAB KẾT HỢP BEVACIZUMAB TẠI BỆNH VIỆN K

Abstract

Objective: To describe the clinical and paraclinical characteristics of patients with unresectable hepatocellular carcinoma (HCC) treated with Atezolizumab plus Bevacizumab at K Hospital. Materials and Methods: A retrospective-prospective descriptive study was conducted, enrolling 70 patients diagnosed with unresectable HCC who received systemic therapy with Atezolizumab in combination with Bevacizumab between December 2020 and May 2025 at K Hospital. Results: The majority of patients were male (88.6%), with a mean age of 53.7 years, and hepatitis B virus (HBV) infection was the predominant etiology (78.6%). Most patients were diagnosed at an advanced disease stage (91.4% BCLC stage C), with a considerable tumor burden: 45.7% had alpha-fetoprotein (AFP) levels ≥ 400 ng/mL, 51.6% had tumors measuring ≥ 7 cm, 51.4% had portal vein thrombosis, and 52.9% presented with extrahepatic metastases. Despite the advanced disease status, liver function and performance status were generally well preserved, with 94.4% classified as Child-Pugh class A, 54.2% as ALBI grade 1, and 58.6% with an ECOG performance status of 0. Notably, 10% of patients received Atezolizumab plus Bevacizumab as second-line therapy following prior tyrosine kinase inhibitor (TKI) treatment failure. Conclusion: This study highlights that Vietnamese patients with HCC are characterized by a younger age at diagnosis, a high prevalence of HBV infection, and a greater tumor burden compared to international clinical trial populations, while maintaining relatively preserved liver function and performance status. These findings support the clinical feasibility of Atezolizumab plus Bevacizumab in routine practice and emphasize the necessity for further investigations in high-risk patient cohorts.